arGEN-X's alliance with Lilly highlights potential of SIMPLE Antibody platform

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced it has entered into an alliance with Eli Lilly and Company ("Lilly") to discover and develop novel therapeutic antibody products against targets submitted by Lilly.

arGEN-X will generate novel human monoclonal antibody (mAb) candidates that act on diverse functional sites on Lilly targets. Lilly will have the option to select the most promising mAb candidates to take forward into preclinical and clinical development and potential commercialization.

Under the terms of the agreement, arGEN-X will receive license fees and research funding,as well as potential milestone payments. Other financial and deal terms were not disclosed. Lilly has exclusive rights to develop and commercialize mAb-based products discovered in the collaboration.

arGEN-X's CEO, Tim Van Hauwermeiren, said: "The signing of this alliance with Lilly is a major highlight for arGEN-X and is evidence of the potential of our SIMPLE Antibody(TM) platform. This collaboration with Lilly is an important step in fulfilling our ambition of becoming a transforming force in the human therapeutic antibody space."